Immunotherapy Targeting Tumor-Associated Macrophages

Yafei Liu* and Rongsi Wang

1 Department of Pharmacy, The Fourth Affiliation Hospital of China Medical University, Shenyang, China, 2 High School of East China Normal University, Shanghai, China

Macrophages are phagocytic cells that play a broad role in maintaining body homeostasis and defense against foreign pathogens; whereas tumor-associated macrophages (TAMs) support tumor growth and metastasis by promoting cancer cell proliferation and invasion, immunosuppression, and angiogenesis, which is closely related to the poor prognosis in almost all solid tumors. Hence, deep-insight knowledge into TAMs can provide an opportunity to discover more effective strategies for cancer therapeutics. So far, a large number of therapeutic agents targeting TAMs are in clinical trials. In this review, we introduce an extensive overview about macrophages and macrophage-targeting agents.

Keywords: macrophage, tumor microenvironment, cancer, immunotherapy, polarization

INTRODUCTION

Cancer, a global public health problem, is the first or second leading cause of death in most countries, and its incidence and mortality are rapidly growing (1). Clinically it is well-acknowledged that tumor sites contain not only cancer cells, but also immune cells, including macrophages, regulatory T (Treg) cells (2), neutrophils (3), mast cells (4), natural killer (NK) cells (5), etc. Macrophages, the main component of the mononuclear phagocyte system (6), are phagocytic cells which play a broad role in maintaining body homeostasis and defense against foreign pathogens; whereas there are a large number of TAMs in tumor microenvironment (TME), which support tumor growth and metastasis by promoting cancer cell proliferation, immunosuppression, invasion, and angiogenesis. Therefore, scientists pay special attention to TAMs when looking for effective cancer treatment strategies. In recent decades, several types of immunotherapies targeting TAMs are playing more and more important roles in the treatment of cancer.

This comprehensive review first summarizes most recent updates regarding macrophage recruitments and functions in tumor, then focuses on the development and evaluation of cancer immunotherapy strategies targeting TAMs including drugs in pre-clinical and clinical stages. Finally, we would like to provide some views and visions of immunotherapy targeting TAMs.

ORIGINS AND POLARIZATION OF MACROPHAGES

Macrophages were first discovered and isolated by Ilya Metchnikoff in the nineteenth century (7). For decades, most people thought that blood-circulating monocytes derived from adult bone marrow (BM) continuously repopulate tissue-resident macrophages (TRMs). It is now well-accepted that a large number of TRMs derive from embryonic precursors, which are from both fetal yolk sac and fetal liver progenitors (8–12). All precursors seed different tissue and differentiate into specialized TRMs on the basis of tissue-specific context (10, 13). Moreover, most tissues also contain macrophages derived from monocytes after birth (13–15). However, some tissues are different, such that monocytes derived from hematopoietic stem cells (HSCs) fleetly take the place...
of embryonic macrophages after birth in the colon, but microglia are rarely from monocytes derived from HSCs under homeostatic conditions (16, 17) (Figure 1A). In tumors, TAMs are usually thought to primarily derive from circulating monocytes, and most recent studies have shown that functions and phenotypes of embryonic-derived and monocyte-derived macrophages are different (13, 18, 19). For example, Pierre-Louis Loyher et al. showed that embryonic-derived TAMs largely correlated with tumor cell growth in vivo, while monocyte-derived TAMs accumulation was associated with enhanced tumor spreading (18). Furthermore, several studies have suggested that TRMs are up to 50% in some murine models such as lung and brain cancer (18, 20).

Macrophages are a type of remarkable plastic cells and can be easily induced by surrounding microenvironment (21, 22). According to different activation methods, macrophages are divided into two extremes (23). Classically activated macrophages (M1 macrophages) and alternatively activated macrophages (M2 macrophages). M1 and M2 macrophages have significant differences in surface receptor expression, tissue distribution, metabolism, cytokine and chemokine production, function, and intracellular signal transduction. M1 macrophages are polarized by lipopolysaccharide (LPS), which binds to the Toll-like receptor 4 (TLR4). Then an inflammatory response is elicited (24), and pro-inflammatory cytokines are released, such as interleukin-1B (IL-1B), IL-6, and tumor necrosis factor-α (TNF-α). These downstream signals recruit more macrophages to resist pathogenic insult (25). M2 macrophages are polarized by cytokines such as IL-4 and IL-13, and release anti-inflammatory cytokines including transforming growth factor-β (TGF-β) and IL-10, inducing processes like membrane remodeling and angiogenesis to promote tissue repair (26, 27). Depending on specific inducing signals and their biological roles, M2 macrophages could be further divided into M2a, M2b, M2c, and M2d (28–32) (Figure 1B). Generally speaking, M1 macrophages mainly kill and clear cancer cells (33, 34), while M2 macrophages mainly support tumor development (35, 36). This M1/M2 concept can easily explain macrophage heterogeneity, but it is too simple to explain the complexity of macrophage activation. Actually, TAMs seem to consist of various populations with a wide range of polarization features or activation states, and their function is determined by microenvironment. Hence, additional studies are necessary to better classify macrophages, and there are several articles about other classifications (37–39).

FUNCTIONS OF MACROPHAGES IN TME

Promoting Tumorigenesis and Progression

TAMs are believed to be the bridge between cancer and inflammation. Some studies show that about 25% of all cancers are related to chronic infection and inflammation (40). The production of chemokines and cytokines are induced by key transcription factors [such as nuclear factor-κB (NF-κB), hypoxia-inducible factor 1α (HIF1α), and signal transducer and activator of transcription 3 (STAT3)] when chronic inflammation occurs, which activates the innate immune system and especially macrophages (41). There is a lot of evidence that the inflammatory microenvironment promotes genetic instability of tumor epithelial cells and tumor-infiltrating immune cells (42, 43). Recently, the inflammatory cytokines IL-23 and IL-17 secreted by TAMs have been shown to be closely related to human colorectal cancer progression (44). For instance, Kupffer cells can promote the progression of hepatocellular carcinoma by secreting mitogens, which relies on the NF-κB signaling pathway (45). Other results show that IL-6 produced by TAMs promotes the development of liver cancer through STAT3 signaling pathway (46), and IL-10 produced by TAMs promotes the development of non-small cell lung cancer through STAT1 signaling (47).

Formation of the Immunosuppressive Microenvironment

Macrophages cannot only kill tumor cells directly when they are activated by interferon-γ (IFN-γ), but also recruit and activate CD8+ cytotoxic T lymphocytes and NK cells by presenting antigens and secreting cytokines to promote the adaptive immunity (48). In addition, T cells can activate monocytes through CD40-CD40L interplay to enhance their expression of major histocompatibility complex class II (MHC II), inducible nitric oxide (iNOS), and TNF (49). In fact, the T helper 2 (T H2) cells, dominating in the TME, activate macrophages to be polarized toward M2 macrophages, which promotes the development of immune suppression (50). Numerous studies have shown that TAMs can directly or indirectly inhibit T cell immune response through different mechanisms. The direct mechanisms include TAMs expressing inhibitory receptors to negatively regulate the activation of T cells by interaction with CD94 (51), expressing T cell immune checkpoint ligands to inhibit T cell functions (52, 53), producing cytokines to maintain a immunosuppressive microenvironment through inducing T reg cell expansion and inhibiting CD4+ and CD8+ T cells (54, 55), and depleting L-arginine and tryptophan to inhibit cytotoxic T cells (56, 57). The indirect mechanisms include TAMs regulating the release of chemokines to control the recruitment of T reg cells (58, 59), and blunting T cell recruitment by regulating the extracellular matrix (ECM) (60).

Abbreviations: AMT, adoptive macrophages transfer; Arg-1, arginase-1; BM, bone marrow; BTK, Bruton’s tyrosine kinase; CAR-M, chimeric antigen receptor macrophage; CAR-T, chimeric antigen receptor T cells; OCL, CC chemokine ligand; CCR, CC chemokine receptor; CSF-1R, CSF-1 receptor; CXCL8, CXCR chemokine ligand 8; ECM, extracellular matrix; FLT1, FMS-like tyrosine kinase 1; HIF1α, hypoxia-inducible factor 1α; HSCs, hematopoietic stem cells; IFN-γ, interferon-γ; iNOS, inducible nitric oxide; Jak2, Janus kinase 2; IL-1B, interleukin-1β; IL-6, IL-6, and tumor necrosis factor-α (TNF-α).
FIGURE 1 | Origins and polarization of macrophages. (A) Macrophages can have three different developmental pathways: fetal yolk sac, fetal liver, and bone marrow. Precursors seed different tissues and differentiate into specialized tissue-resident macrophages on the basis of tissue-specific context, and they have dramatical

Continued
Promoting Invasion and Metastasis
Cancer metastasis is a complicated event, which plays a crucial role in the cause of morbidity and mortality (61, 62). It is worth noting that macrophages play an important role in tumor cells invasion and metastasis. They facilitate the escape of tumor cells from the basement membrane through the dense stroma by producing proteases to promote ECM degradation (63). Furthermore, several factors, such as macrophage-colony stimulating factor (M-CSF/CSF-1), can stimulate macrophages to promote tumor invasion (64, 65). Metastasis-associated macrophages (MAMs), a unique population of macrophages, have been identified are found to be recruited by CC chemokine ligand (CCL) 2 (66, 67). MAMs promote cancer cell invasion and metastasis by FMS-like tyrosine kinase 1 (FLT1) receptor tyrosine kinase signaling in a mouse model of breast cancer (68). In addition, several studies show that the activation of the CCL2/CC chemokine receptor (CCR) 2 axis is very important in MAM-mediated metastasis (66, 67, 69). Recent studies have shown that pre-metastatic niche (PMN) is a pre-requisite in mediating tumor cell metastasis. Primary tumor cells are thought to initiate the formation of PMN by the secretion of proinflammatory cytokines, chemokines, and angiogenic factors that recruit BM-derived cells into future metastatic sites, and these cells induce PMN formation in reverse (70). For example, CXCL1 secreted by TAMs was reported to recruit CXCR2<sup>+</sup> myeloid suppressor cells to promote liver PMN formation (71, 72).

Promoting Angiogenesis
Angiogenesis is necessary for tumor growth and metastasis, which is regarded as a “hallmark” of cancer (73). Accumulating evidence emphasizes the crucial roles of macrophages in promoting tumor angiogenesis, and TAMs is closely related to the number of blood vessels in the tumor (74). Hypoxia is the primary driver of angiogenesis, and some studies show that anoxic areas of tumors, especially the necrotic tissue, have large numbers of macrophages due to the releasing of endothelins, vascular endothelial growth factor (VEGF), high mobility group 1, CCL2, CXC chemokine ligand 8 (CXCL8), CXCL12, and CSF-1 (75). The increased expression of hypoxia-inducible transcription factors on TAMs up-regulates the transcription of various genes in hypoxic tumor sites, which responds to hypoxia and promotes tumor cells proliferation, metabolism, and angiogenesis (75–77). In a CSF-1 knockout mice model, macrophage number was found to significantly reduce in the tumor site, accompanied by impaired vascular development (78). In addition, tumor endothelium-released angiopoietin-2 (TIE-2) was reported to play an significant role in tumor angiogenesis by recruiting monocytes that express the TIE-2 receptor (79). Furthermore, results of gene analysis indicated that TAMs could up-regulate the expression of various factors, which participate in tumor angiogenesis and provide nutrients for tumor growth (39).

IMMUNOTHERAPY-TARGETING TAMS IN CANCER

Restoration of Macrophage Phagocytosis
CD47 has been found expressed on many tumor cells, and it can bind with signal regulatory protein α (SIRPα) on the membrane surface of macrophages, which down-regulates macrophage phagocytosis of tumor cells (80, 81). In the past few years, a number of clinical trials have been conducted to determine various treatments that block CD47/SIRPα (Figure 2) (82). Anti-CD47 antibody treatment could inhibit tumor growth in a pediatric brain malignancies model (83). Anti-CD47 antibody in combination with TTI-621, a SIRPα-Fc fusion protein that could block the binding between SIRPα and CD47, promotes phagocytosis of tumor cells in a B-cell lymphoma mouse model (84). Hu5F9-G4, a human monoclonal antibody targeting against CD47 has been tested in a tumor therapy as a single agent, as well as in combination with cetuximab. Nevertheless, anti-CD47 therapies may increase the occurrence of transient anemia, because HSCs and red blood cells extensively express CD47 (85, 86). Furthermore, there are other “don’t eat me” signals including programmed cell death ligand 1 (PD-L1), MHC 1 component β2-microglobulin, and CD24, and antibodies which direct against the interaction of these signals with their macrophage surface receptors have demonstrated therapeutic potential in several cancers (87–89).

Inhibition of Macrophage Recruitment
Under tumor microenvironment, monocytes are rapidly recruited into tumor (90). Chemokines CCL2, CCL3, CCL4 and cytokines IL-1β, and CSF-1 have proven to contribute to the monocyte recruitment into tumors (91, 92). It is shown that CCL2 expression is up-regulated by macrophages and tumor cells in TME (93–95). Moreover, the high expression of CCL2 has a correlation with the poor prognosis in many human and murine tumors (96). CCL2 promotes monocytes recruitment by stimulating CCR2. In fact, blocking CCL2/CCR2 not only inhibits the monocyte infiltration but also prevents immunosuppressive polarization of macrophages (97, 98). Currently, a number of treatments targeting CCL2/CCR2 are in clinical trials (99) (Figure 2). A CCR2 inhibitor, PF-04136309, has been demonstrated to effectively inhibit tumor growth in pancreatic cancer patients (100, 101). CCL2 antibody treatment has proven to suppress tumor metastasis in a breast cancer model (96). Moreover, IL-1β has been identified as a chemoattractant target for cancer treatment. An IL-1 receptor antibody has been demonstrated to suppress inflammatory...
Targeting TAM strategies in cancer treatments. Several critical targets have been identified that regulate TAMs recruitment, polarization, survival, and phagocytosis during tumor progression. Targeting key receptors or signaling molecules can modulate these macrophage properties and suppress tumor progression. For example, targeting CSF1R can suppress the survival of TAMs. Agonists of CD40 can promote TAMs toward a proinflammatory phenotype that can suppress tumor. Inhibitors of CCR2 or CXCL2 can inhibit monocyte recruitment. Targeting CD47 on tumor cells can promote macrophage phagocytosis of tumor cells. These therapeutic strategies are developed to promote effective antitumor immune responses and many drug candidates are currently investigated in clinical trials for cancer therapy.

Controlling Macrophage Proliferation and Survival

CSF-1 receptor (CSF-1R), a tyrosine kinase receptor, plays a key role in regulating macrophage proliferation and survival (103). Several studies show that blocking CSF-1/CSF-1R inhibited immunosuppressive macrophage polarization, reduced tumor cell proliferation, and promoted apoptosis, therefore suppressing tumor progression and prolonged life survival (104, 105) (Figure 2). M279, a CSF-1R antibody, blocking both CSF-1 and IL-34, has been shown to inhibit tumor growth and improve survival rate in a spontaneous breast tumor model (106, 107). BLZ945, a small-molecule CSF-1R inhibitor has been reported to be therapeutically effective in glioma and breast cancer mouse models (108). Moreover, a number of CSF-1R-specific inhibitors, including PLX3397, PLX7486, and BLZ945, have been tested in clinical trials (109, 110). Especially, PLX3397, exhibiting higher affinity to CSF-1R, has demonstrated a better effect for tenosynovial giant cell tumor therapy, and the drug has been advanced into clinical trial phase III (111). In addition, several FDA-approved tyrosine kinase inhibitors, such as targeting c-KIT and VEGFR, have also been shown to have a binding activity with the CSF-1R kinase (112).

Modulation of Macrophage Phenotype

PI-3 kinase γ (PI3Kγ) has been identified as a promising target for modulating macrophage phenotype and proinflammatory cytokine expression (113) (Figure 2). IPI-549, a PI3Kγ inhibitor, is currently tested in Phase 1b clinical trials for several solid tumors, in combination with nivolumab. Bruton’s tyrosine kinase (BTK), a downstream of PI3Kγ, has been investigated as a target for cancer treatment. In line with studies, ibrutinib, a BTK inhibitor, has been advanced in Phase III clinical trials for pancreatic adenocarcinoma treatment and in Phase II clinical trials for relapsed or refractory solid tumor therapy in combination with durvalumab. Janus kinase 2 (JAK2) and STAT3 also have been regarded as potential targets for macrophage accumulation and tumor growth in lung and breast cancer mouse models (100). Moreover, in combination with fluorouracil and bevacizumab, Anakinra, an IL-1 receptor antibody, has been shown to prolong patients’ life in a colorectal carcinoma Phase II clinical trial (102) (Table 1).
TABLE 1 | Clinical trials of macrophage-targeting agents.

| Drug      | Company                  | Clinical trial number | Tumor type                                      | Phase |
|-----------|--------------------------|-----------------------|-------------------------------------------------|-------|
| CD47      | Hu5F9-G4                 | Forty Seven           | NCT02953782 Advanced solid malignancies and colorectal carcinoma + cetuximab | I     |
| TTI-621   | Trillium                 | NCT02663518           | Advanced solid malignancies                     | I     |
| CD40      | SEA-CD40                 | Seattle Genetics      | NCT02737699 Solid tumors + pembrolizumab        | I     |
| APX005M   | Apexigen                | NCT03288902           | Pediatric CNS                                   | I     |
| CP-870,893| VLAST Corporation        | NCT0103635            | Metastatic melanoma + tremelimumab (antiCTLA-4) | I     |
| R07009879 | Roche                    | NCT02760797           | Advanced solid tumors + anti-PDL1               | I     |
| CSF1R     | BLZ945                   | Novartis              | NCT02588443 Advanced solid tumors single agent  | I     |
| Emactuzumab| Hoffman La Roche       | NCT02323191           | Advanced solid tumors + PDR001                  | I     |
| IMC-CS4   | Lilly                    | NCT01346388           | Advanced solid tumors                           | I     |
| CCR2      | BMS-813160               | Bristol Meyers Squibb | NCT02471716 Tenosynovial giant cell tumor       | II    |
| CCX872-B  | ChemoCentryx            | NCT03158272           | Advanced malignancy + nivolumab                 | I     |
| MLN1202   | Millennium              | NCT02526017           | Advanced solid tumors + nivolumab               | I     |
| IL1Ra     | Anakiria                 | NCT02265536           | Advanced breast, prostate cancer                | I     |
| TLR4      | GSK1795091               | NCT03153410           | PDAC + cyclophosphamide pembrolizumab, GVAX     | I     |
| Stat3     | TTI-101                  | NCT03195699           | Advanced cancers                                | I     |
| PI3Ky     | IPI-549                  | NCT02637531           | Advanced solid tumors + nivolumab               | Iib   |
| BTK       | Ibrutinib                | NCT02599324           | Renal cell, urothelial, gastric, colon, pancreatic adenocarcinoma | III   |
|           |                          | NCT02436688           | PDAC, gemicitabine + nab-paclitaxel              | Iib/II|
|           |                          | NCT02403271           | Relapsed or refractory solid tumors + durvalumab| III   |

repolarization (114). The STAT3 inhibitor TTI-101 is currently investigated in a Phase I clinical trial for advanced cancers, and the JAK2 inhibitor has been applied for the treatment of psoriasis, myelofibrosis, and rheumatoid arthritis in clinic (115).

CD40 is mainly expressed on antigen presenting cells, monocytes, and some tumor cells. CD40 ligation in macrophages induces secretion of proinflammatory cytokines and promotes macrophage polarization toward a proinflammatory macrophage. Several anti-CD40 antibodies and CD40 ligands, such as RO7009789, APX005M, are currently under test and evaluation in clinical trials for solid tumors (Figure 2). Interestingly, unlike other activatory Fc receptors, the antibody Fc domain with inhibitory FcγRIIB is required for anti-40 antibody because of its agonistic immunostimulatory activity. In particular, CP-870893, a Pfizer anti-CD40 antibody of IgG2 subclass, has been shown to be more competitive in immunostimulation compared to other drugs in clinical trials (116). Moreover, TLR agonist treatment has been studied and
developed for cancer therapy because TLRs stimulation can polarize macrophages toward a proinflammatory phenotype.

**Metabolic Modulation of TAMs**

To support specialized cellular activities, macrophages use diverse metabolic pathways for energy and metabolite at different states (117). Metabolic changes contribute to the regulation of macrophage polarization, and TAMs display an immunosuppressive phenotype that is defined by the production of ornithine and polyamines through the arginase pathway as well as by expression of TNF-α cytokines that include IL-10 (118–120). Several studies have shown that the tumor microenvironment, featured poor nutrient and acidic environment, directly induced macrophages to adopt immunosuppressive phenotypes (121–123). For example, lactate, a byproduct of tumor cells, can promote monocytes and macrophages toward to immunosuppressive macrophage polarization in B16 melanoma and lung carcinomas mouse model (121). Moreover, the tumor microenvironment in melanomas characterized by acid has been reported to promote immunosuppressive polarization of TAMs, including upregulating arginase and VEGF expression (124). Collectively, these studies have shown that altering the metabolic pathways of TAMs to repolarize macrophages might be an effective strategy for antitumor functions.

The PI3K/Akt/mTOR myeloid signaling pathway plays a key role in regulation of TAMs metabolism by promoting L-arginine metabolism, a curial section that could promote immunosuppression. The gene and protein expression of Arginase-1 (Arg-1) in TAMs up-regulates and inhibition of PI3Kγ can suppress Arg-1 expression and activity (90). Additionally, the deletion of PI3Kγ promotes the expression of the enzyme NOS, which promotes the production of the free radical and NO to function as anti-tumor. Kaneda et al. reported that IPI-549, a PI3Kγ inhibitor, inhibited lung carcinoma and breast tumors by promoting TAM-immunostimulatory response (125). Moreover, mTORC1 and mTORC2 also play a key role in the metabolic programming of macrophages by sensing nutrients, oxygen, and metabolites. Rapamycin, an mTORC1 inhibitor, has been reported to promote macrophages toward the proinflammatory phenotype with an anti-tumor effect (126) (Figure 2).

**Adoptive Macrophages Transfer**

Adoptive cell transfer is an emerging method of immunotherapy, which kills and removes cancer cells by the infusion of immune cells (127). Macrophages have the capacity to penetrate tumors (128), which may kill tumor cells where CAR-T therapy has fallen (129). Therefore, adoptive macrophage transfer (AMT) has become a hot research field for tumor detection and treatment lately. Amin Aalipour et al. used engineered macrophages as diagnostic sensors to successfully detect tumors as small as 4 mm in diameter and show better sensitivity than traditional cancer biomarkers (130). Recently, Michael Klichinsky et al. described an anti-HER2 CAR-macrophage (CAR-M) that significantly reduced metastatic tumor burden (131). A cellular IFN-γ “backpack” for macrophages was reported to promote phagocytosis and polarize macrophages toward the M1 phenotype, which further slows down the tumor growth in a murine breast cancer model (132). Overall, the adoptive transfer therapy of macrophages is still in the research stage, and there are many problems to be solved, such as the establishment of pre-clinical models to evaluate the efficacy and safety of AMT. In addition, the way to efficiently transfer genes into human macrophages is still challenging and needs further study.

**DISCUSSION**

Various strategies targeting TAMs have been studied for cancer therapy, and some treatments have been advanced into clinical trials. However, because of complexity of tumors, a combination therapy is usually adopted to maximize the anti-tumor effect; whether currently targeted signaling pathways therapeutically overlap or synergize in vivo remains to be explored. More importantly, current researches do not have a thorough understanding of these targets, and their other functions are often overlooked in cancer treatment. Besides, with multiple targets being identified and drugs being tested for the modulation of TAMs, drug delivery technologies have been advanced to further enhance the efficacy of these drugs, through the way of improving stability, selectivity, and intracellular delivery efficiency, etc. CAR-M, as an emerging strategy for cancer therapeutic, is still in research stage. Currently, overcoming the challenge that genes transfer into human macrophages and finding effective solid tumor targets are the main tasks. Perhaps CAR-M in the future is to adopt multiple macrophages having different functions rather than a single population.

TAMs represent a heterogeneous population with different functions according to different origins and contexts. Consequently, it is necessary to understand this heterogeneity and how it evolves during the progression of cancer and also following therapy in human, not mouse, models. In this context, the extensive use of single-cell RNA sequencing, multiplex immunohistochemistry, and mass cytometry will considerably increase our knowledge about TAMs, which is essential for the adoption of precision medicine and good prediction of patient responses. Admittedly, many questions remain regarding to properties and functions of macrophages in TME. However, with the deeper understanding of macrophage diversity through single-cell sequencing and other technologies, we believe that TAM-targeted treatment will be an important addition for cancer immunotherapy.

**AUTHOR CONTRIBUTIONS**

YL conceived the concept and wrote the manuscript. RW edited and improved the manuscript. All authors contributed to the article and approved the submitted version.
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492

2. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. Nat Rev Clin Oncol. (2019) 16:536–71. doi: 10.1038/s41571-019-0175-7

3. Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: going pro. Cancers. (2019) 11:564. doi: 10.3390/cancers11040564

4. Gorzalczyanska Y, Sagi-Eisenberg R. Role of mast cell-derived adenosine in cancer. J Int Med. (2019) 20:2603. doi: 10.3390/jim20102603

5. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. (2016) 16:7–19. doi: 10.1038/nrc.2015.5

6. Hume DA. The mononuclear phagocyte system. Curr Opin Immunol. (2006) 18:49–53. doi: 10.1016/j.coi.2005.11.008

7. Cooper MD, Alder MN. The evolution of adaptive immune systems. Cell. (2014) 124:815–22. doi: 10.1016/j.cell.2014.07.017

8. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity. (2014) 40:91–104. doi: 10.1016/j.immuni.2013.11.019

9. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity. (2014) 41:21–35. doi: 10.1016/j.immuni.2014.06.013

10. Hoeffel G, Ginhoux F. Fatal monocytes and the origins of tissue-resident macrophages. Cell Immunol. (2018) 330:5–15. doi: 10.1016/j.cellimm.2018.01.001

11. Bian Z, Gong Y, Huang T, Lee CZW, Bian L, Bai Z, et al. Deciphering human monocyte-derived macrophages from the central nervous system by flow fate mapping analysis reveals that adult microglia derive from primitive embryonic and adult-derived resident cardiac macrophages. J Exp Med. (2016) 207:3435–46. doi: 10.1084/jem.201603271

12. Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and plasticity of tissue macrophages. Immunity. (2015) 41:21–35. doi: 10.1016/j.immuni.2015.04.004

13. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. (2018) 233:6425–40. doi: 10.1002/jcp.26429

14. Wang Q, Ni H, Lan L, Wei X, Xiang R, Wang Y. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res. (2010) 20:701–12. doi: 10.1038/cr.2010.52

15. Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol. (2018) 8:49. doi: 10.3389/fonc.2018.00049

16. Canli O, Nicolas AM, Gupta J, Finkelmeier F, Goncharova O, Pesic M, et al. Macrophage diversity enhances tumor progression and metastasis. Cell. (2018) 173:887–904. doi: 10.1016/j.cell.2018.03.014

17. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel guidelines. Int J Cancer. (2017) 141:39–51. doi: 10.1002/ijc.31399

18. Chen Z, Feng X, Hering J, Garcia VA, Nie K, Pong WW, et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. (2017) 77:2266–78. doi: 10.1158/0008-5472.CAN-16-2310

19. Bowman RL, Klemm F, Akkari L, Pyonenteck SM, Sevenich L, Quail DE, et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. (2016) 17:2445–59. doi: 10.1016/j.celrep.2016.10.052

20. Akabe Y, Medzhitov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell. (2014) 157:832–44. doi: 10.1016/j.cell.2014.04.016

21. Stout RD, Jiang C, Matta B, Tetzlief J, Watkins SK, Sutcliffe J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol. (2005) 175:342–9. doi: 10.4049/jimmunol.175.1.342
enhancing retention of metastasis-associated macrophages. J Exp Med. (2015) 212:1043–9. doi: 10.1084/jem.20141836

78. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE. (2009) 4:e5652.
doi: 10.1371/journal.pone.0005652

79. Qian BZ, Zhang H, Li J, He T, Yeo EJ, Soong DY, et al. FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. J Exp Med. (2015) 212:1433–48. doi: 10.1084/jem.20141555

80. Kitamura T, Doughty-Shenton D, Cassetta L, Fragkogianni S, Brownlie D, Kato Y, et al. Monocytes differentiate to immune suppressive precursors of metastasis-associated macrophages in mouse models of metastatic breast cancer. Front Immunol. (2017) 8:2004. doi: 10.3389/fimmu.2017.02004

81. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the pre-metastatic niche. Cancer Cell. (2009) 15:35–44. doi: 10.1016/j.ccr.2008.11.012

82. Zheng Y, Wang N, Wang S, Yang B, Situ H, Zhong L, et al. XIAOP1 formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling. Cell Commun Signal. (2020) 18:48. doi: 10.1186/s12964-020-02520-6

83. Wang D, Sun H, Wei J, Cen B, DuBois RN. CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. (2017) 77:3655–65. doi: 10.1158/0008-5472.CAN-16-3199

84. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013

85. Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonic N. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. (2002) 440:583–8. doi: 10.1007/s004280100458

86. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. (2008) 8:618–31. doi: 10.1038/nrc2444

87. Burke B. Expression of HIF-1α by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol. (2002) 196:204–12. doi: 10.1002/path.1029

88. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. (2004) 104:2224–34. doi: 10.1182/blood-2003-1109

89. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zuo L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. (2006) 66:11238–46. doi: 10.1158/0008-5472.CAN-06-1278

90. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. (2011) 19:512–26. doi: 10.1016/j.ccr.2011.02.005

91. Zhao H, Wang J, Kong X, Li E, Liu Y, Xu D, et al. CD47 promotes tumor invasion and metastasis in non-small cell lung cancer. Sci Rep. (2016) 6:29719. doi: 10.1038/srep29719

92. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chaop M, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. (2009) 138:271–85. doi: 10.1016/j.cell.2009.05.046

93. Nangamangong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. (2017) 114:206–21. doi: 10.1016/j.addr.2017.04.010

94. Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, et al. Disrupting the CD47-SIRPalpha-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. (2017) 9:eaal2968. doi: 10.1126/scitranslmed.aal2968

95. Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, et al. TTI-621 (SIRPalphaFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res. (2017) 23:1090–9. doi: 10.1158/1078-0432.CCR-16-1700

96. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Preclinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE. (2015) 10:e0137345. doi: 10.1371/journal.pone.0137345
86. Ho CC, Guo N, Sockolosky JT, Ring AM, Weiskopf K, Ozkan E, et al. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis. *J Biol Chem.* (2015) 290:12650–63. doi: 10.1074/jbc.M115.648220

87. Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosentel B, Yiu YY, et al. Engagement of MHC class I by the inhibitory receptor LILR1 suppresses macrophages and is a target of cancer immunotherapy. *Nat Immunol.* (2018) 19:76–84. doi: 10.1038/s41590-017-0004-z

88. Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage siglecs-10 is a target for cancer immunotherapy. *Nature.* (2019) 572:392–6. doi: 10.1038/s41586-019-1456-0

89. O’Donnell JS, Long GV, Scigolr RA, Teng MW, Smyth MJ. Resistance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. *Prostate.* (2006) 66:1311–8. doi: 10.1002/pros.20968

90. Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon DH, et al. Overcoming resistance to checkpoint blockade therapy targeting FMS receptor signaling. *Blood.* (2012) 119:1810–20. doi: 10.1182/blood-2011-09-379214

91. Schmid MC, Franco I, Kang SW, Hirsch E, Quilliam LA, Varner JA. PI3-kinase gamma promotes lung cancer-induced bone resorptive lesions in vivo. *Cancer Discov.* (2010) 1:e60226. doi: 10.1371/journal.pone.0060226

92. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. *Cancer Res.* (2012) 72:876–86. doi: 10.1158/0008-5472.CAN-11-1792

93. Cai Z, Chen Q, Chen J, Lu Y, Xiao G, Wu Z, et al. Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. *Neoplasia.* (2009) 11:228–36. doi: 10.1593/neo.81282

94. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. *Prostate.* (2006) 66:1311–8. doi: 10.1002/pros.20964

95. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes. *Cancer Treat Rev.* (2016) 47:286––710. doi: 10.1016/j.ctrv.2016.11.007

96. Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon DH, et al. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis. *J Biol Chem.* (2015) 290:12650–63. doi: 10.1074/jbc.M115.648220

97. Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosentel B, Yiu YY, et al. Engagement of MHC class I by the inhibitory receptor LILR1 suppresses macrophages and is a target of cancer immunotherapy. *Nat Immunol.* (2018) 19:76–84. doi: 10.1038/s41590-017-0004-z

98. barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage siglecs-10 is a target for cancer immunotherapy. *Nature.* (2019) 572:392–6. doi: 10.1038/s41586-019-1456-0

99. O’Donnell JS, Long GV, Scigolr RA, Teng MW, Smyth MJ. Resistance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. *Prostate.* (2006) 66:1311–8. doi: 10.1002/pros.20968

100. Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon DH, et al. Overcoming resistance to checkpoint blockade therapy targeting FMS receptor signaling, macrophage production and osteoclastogenesis. *Leukemia.* (2008) 22:649–52. doi: 10.1038/sj.leu.2404944

101. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. *N Engl J Med.* (2015) 373:428–37. doi: 10.1056/NEJMoa1411366

102. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ, Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. *Leukemia.* (2009) 23:590–4. doi: 10.1038/leu.2008.237

103. De Henua O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. *Nature.* (2016) 539:443–7. doi: 10.1038/nature20554

104. Pathria P, Gotthardt D, Pechal-Murphy M, Putz EM, Holcmann M, Schedler M, et al. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer. *Nature Immunology.* (2015) 16:998529. doi: 10.1038/nature20540

105. Huang SC, Smith AM, Everts B, Colonna M, Pearce EL, Schilling JD, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses cellular phagocytosis. *J Biol Chem.* (2015) 290:12650–63. doi: 10.1074/jbc.M115.648220

106. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. *Clin Cancer Res.* (2013) 19:1035–20. doi: 10.1158/1078-0432.CCR-12-0376

107. Huang SC, Smith AM, Everts B, Colonna M, Pearce EL, Schilling JD, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses cellular phagocytosis. *J Biol Chem.* (2015) 290:12650–63. doi: 10.1074/jbc.M115.648220

108. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. *Clin Cancer Res.* (2013) 19:1035–43. doi: 10.1158/1078-0432.CCR-12-0464

109. Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. *Nature.* (2014) 511:167–76. doi: 10.1038/nature13132

110. Covarrubias AJ, Aksoylar HI, Horng T. Control of macrophage metabolism and activation by mTOR and Akt signaling. *Semin Immunol.* (2015) 27:286–96. doi: 10.1016/j.sım.2015.08.001

111. Huang SC, Smith AM, Everts B, Colonna M, Pearce EL, Schilling JD, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. *Immunity.* (2016) 45:817–30. doi: 10.1016/j.immunity.2016.09.016

112. Porta C, Sica A, Riboldi E. Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy. *FEBS J.* (2018) 285:77–33. doi: 10.1111/febs.14288

113. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature.* (2014) 513:559–63. doi: 10.1038/nature13490
122. Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. *Cell Metab.* (2019) 30:36–50. doi: 10.1016/j.cmet.2019.06.001

123. Larionova I, Kazakova E, Patsycheva M, Kuzhishkowska Transcriptional J. Epigenetic and metabolic programming of tumor-associated macrophages. *Cancers.* (2020) 12:1411. doi: 10.3390/cancers12061411

124. Kuchuk O, Tuccitto A, Citterio D, Huber V, Camisaschi C, Milione M, et al. pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. *Oncoimmunology.* (2018) 7:e1445452. doi: 10.1080/2162402X.2018.1445452

125. Kaneda MM, Messer KS, Rakainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3Kgamma is a molecular switch that controls immune suppression. *Nature.* (2016) 539:437–42. doi: 10.1038/nature19834

126. Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. *Nat Rev Immunol.* (2015) 15:599–614. doi: 10.1038/nri3901

127. Fefer A. Immunotherapy and chemotherapy of moloney sarcoma virus-induced tumors in mice. *Cancer Res.* (1969) 29:2177–83.

128. Ritchie D, Mileskin L, Wall D, Bartholomew J, Thompson M, Coverdale J, et al. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. *Cancer Immunol Immunother.* (2007) 56:155–63. doi: 10.1007/s00262-006-0181-3

129. Lee S, Kivimae S, Dolor A, Szoka FC. Macrophage-based cell therapies: the long and winding road. *J Control Release.* (2016) 240:527–40. doi: 10.1016/j.jconrel.2016.07.018

130. Aalipour A, Chuang HY, Murty S, D’Souza AL, Park SM, Gulati GS, et al. Engineered immune cells as highly sensitive cancer diagnostics. *Nat Biotechnol.* (2019) 37:531–9. doi: 10.1038/s41587-019-0064-8

131. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nat Biotechnol.* (2020) 38:947–53. doi: 10.1038/s41587-020-0462-y

132. Wyatt Shields C, IV, Evans MA, Wang LL-W, Baugh N, Iyer S, Wu D, et al. Cellular backpacks for macrophage immunotherapy. *Sci Adv.* (2020) 6:eaaz6579. doi: 10.1126/sciadv.aaz6579

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.